Understanding how viruses affect cancer treatment response
Part of Infections clinical trials.
This study looks at how viruses like HPV, HIV, and EBV affect the tumor environment and why some cancers become resistant to treatment. It aims to understand these mechanisms to improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with one of the specified cancers: oropharyngeal, non-small cell lung, anal canal, or a large B-cell lymphoma.
- You are being treated at one of the listed hospitals in the Paris area (AP-HP).
- You have stored tumor tissue from a biopsy or surgery that was taken before starting cancer treatment.
- For some cancers, you also need a second tumor sample taken after the cancer progressed during treatment.
- You agree to participate and are covered by French health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor samples from people with certain cancers to compare those caused by viruses (like HPV, HIV, or EBV) with those not caused by viruses. The goal is to understand why some tumors respond differently to treatments, which may help improve future treatment approaches.
This study collects blood and/or tumor-related samples to map how your immune system recognizes cancer. It aims to better understand immune targets and immune cell types, which may help guide future cancer treatments for certain virus-related cancers.
This study looks at whether HPV infection stays in the body during and after standard radiation treatment for cervical cancer, and if that affects how well the treatment works. It aims to understand more about why some people respond better than others.
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
Hear when a new Lymphoma Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.